Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has earned an average recommendation of “Hold” from the ten analysts that are presently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $32.43.

TNDM has been the subject of a number of analyst reports. Zacks Investment Research upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $7.50 target price for the company in a research note on Thursday, September 28th. Piper Jaffray Companies reiterated a “hold” rating and issued a $15.00 target price on shares of Tandem Diabetes Care in a research note on Friday, October 6th. Finally, Wedbush reiterated an “outperform” rating and issued a $17.00 target price (down from $50.00) on shares of Tandem Diabetes Care in a research note on Tuesday, October 10th.

Shares of Tandem Diabetes Care (NASDAQ TNDM) opened at 2.67 on Wednesday. Tandem Diabetes Care has a 52-week low of $2.27 and a 52-week high of $65.50. The stock has a 50 day moving average of $5.52 and a 200 day moving average of $7.26. The firm’s market cap is $13.41 million.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Thursday, July 27th. The medical device company reported ($4.40) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($4.80) by $0.40. The firm had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $21.74 million. Tandem Diabetes Care had a negative net margin of 110.70% and a negative return on equity of 1,177.11%. The company’s revenue was down 7.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($6.00) earnings per share. Equities analysts predict that Tandem Diabetes Care will post ($17.06) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Tandem Diabetes Care, Inc. (TNDM) Receives Consensus Rating of “Hold” from Analysts” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/25/tandem-diabetes-care-inc-tndm-receives-consensus-rating-of-hold-from-analysts.html.

In related news, CEO Kim D. Blickenstaff bought 285,700 shares of the company’s stock in a transaction that occurred on Friday, October 13th. The shares were acquired at an average price of $3.50 per share, with a total value of $999,950.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 20.90% of the company’s stock.

A number of hedge funds have recently made changes to their positions in TNDM. Bank of America Corp DE increased its position in Tandem Diabetes Care by 88.6% during the first quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock worth $1,032,000 after acquiring an additional 404,452 shares during the period. Russell Investments Group Ltd. bought a new position in Tandem Diabetes Care during the first quarter worth $360,000. Keybank National Association OH increased its position in Tandem Diabetes Care by 32.7% during the second quarter. Keybank National Association OH now owns 293,206 shares of the medical device company’s stock worth $235,000 after acquiring an additional 72,177 shares during the period. Finally, Vanguard Group Inc. increased its position in Tandem Diabetes Care by 2.7% during the second quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock worth $987,000 after acquiring an additional 32,991 shares during the period.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related companies with MarketBeat.com's FREE daily email newsletter.